Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
08/2003
08/21/2003WO2002077236A3 Compositions and methods relating to lung specific genes and proteins
08/21/2003WO2002072140A3 Mhc-i-restricted presentation of hiv-1 virion antigens without viral replication. application to the stimulation of ctl and vaccination in vivo; analysis of vaccinating composition in vitro
08/21/2003WO2002070695A3 Tumor associated proteins
08/21/2003WO2002064748A3 Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
08/21/2003WO2002064731B1 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
08/21/2003WO2002062999A3 Proteins and nucleic acids encoding same
08/21/2003WO2002061090A3 Prokaryotically produced antibodies and uses thereof
08/21/2003WO2002057452A3 Human proteins, polynucleotides encoding them and methods of using the same
08/21/2003WO2002053174A3 Controlled release pharmaceutical systems
08/21/2003WO2002048175A3 Mhc class i associated peptides for prevention and treatment of tuberculosis
08/21/2003WO2002046416A3 Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
08/21/2003WO2002046224A3 Compositions and methods relating to lung specific genes and proteins
08/21/2003WO2002044209A3 Cytonkine receptor zcytor19
08/21/2003WO2002040535A3 Compositions and methods relating to ovary specific genes and proteins
08/21/2003WO2002036615A3 Methods for producing and improving therapeutic potency of binding polypeptides
08/21/2003WO2002036611A3 Immunomodulatory peptides derived from heat shock proteins and uses thereof
08/21/2003WO2002035240A3 Methods for identifying compounds for regulating muscle mass or function using vasoactive intestinal peptide receptors
08/21/2003WO2002020722A9 Methods and compositions for in vitro targeting
08/21/2003WO2002020047A9 Chlamydial peptides and their mimics in demyelinating disease
08/21/2003WO2002010392A9 Mammalian dna binding membrane-associated protein-encoding gene and uses
08/21/2003WO2002006344A3 Rtvp based compositions and methods for the treatment of prostate cancer
08/21/2003WO2002004009A3 Method for treating cancer using an interleukin- 4 antagonist
08/21/2003WO2001092581A3 Compositions and methods for the therapy and diagnosis of ovarian cancer
08/21/2003US20030159182 Production of therapeutic proteins in transgenic cereal crops
08/21/2003US20030159158 Method for identifying an agonist of neuronal calcium sensor-1 (NCS-1), for therapy of CNS disorders
08/21/2003US20030158399 Compositions and methods for the treatment and diagnosis of immune disorders
08/21/2003US20030158396 Identification of polynucleotides encoding novel helicobacter polypeptides in the helicobacter genome
08/21/2003US20030158390 Protein; Escherichia culture product; genetic engineering; fusion
08/21/2003US20030158388 MAGE-10 encoding cDNA, the tumor rejection antigen precursor MAGE-10, antibodies specific to the molecule, and uses thereof
08/21/2003US20030158383 Ehrlichia chaffeensis 28 kDa outer membrane protein multigene family
08/21/2003US20030158381 Novel insulin/igf/relaxin family polypeptides and dnas thereof
08/21/2003US20030158217 Succinate and malonate complexes treatment of abnormal cell growth, such as cancer, and overexpression of erbB2, and inducing cell death
08/21/2003US20030158149 Administering a nucleoside or a nucleoside analog, such as (5'-fluoro-5-methyl-beta-arabinofuranosyl-uridine) or salt or prodrug that suppresses the expression of hepatitis B surface or preS1 antigen in the host 100-fold
08/21/2003US20030158138 Nucleic acid construct encoding a processing component derived from the N-terminal region of the hepatitis virus ORF2, and an antigenic polypeptide
08/21/2003US20030158136 Materials and methods relating to immune responses to fusion proteins
08/21/2003US20030158134 Use of HIV Tat protein or polynucleotide, HIV Nef protein or polynucleotide, HIV Tat protein or polynucleotide linked to HIV Nef protein or polynucleotide and HIV gpl20 protein or polynucleotide in manufacture of vaccine against hiv
08/21/2003US20030158131 DNA vectors containing mutated HIV proviruses
08/21/2003US20030158099 Cancer therapy
08/21/2003US20030158085 For diagnosis and therapy of pancreatic disorders, particularly type I diabetes
08/21/2003US20030157705 Engineered recombinant molecule that regulates humoral and cellular effector functions of the immune system
08/21/2003US20030157703 Recombinant herpesvirus of turkeys and use thereof
08/21/2003US20030157692 Papillomavirus infected epithelial cells and methods of producing infectious papillomavirus in epithelial cells and uses thereof
08/21/2003US20030157660 Non-M, non-O HIV-1 strains, fragments and uses
08/21/2003US20030157650 Recombinant P. vivax merozoite protein-1 p42 vaccine
08/21/2003US20030157637 Comprises antigenic complex for use in raising an antibody response directed against Porphyromonas gingivalis; prevention and treatment of oral diseases
08/21/2003US20030157633 Comprises nucleotide sequences coding transmembrane protein/transport protein (TRPV3) for treating pain, inflammation and skin disorders
08/21/2003US20030157562 Protein is characterized in that it elicits an immunological response from a mammal; has been prepared by expression in a bacterium other than Borrelia burgdorferi; free of other Borrelia proteins and has specific amino acid sequence
08/21/2003US20030157541 Central nervous system disorders; cardiovascular disorders;antiasthma agents
08/21/2003US20030157482 Binding labeled antibody to protein; measurement; calibration
08/21/2003US20030157479 Antigen arrays for treatment of allergic eosinophilic diseases
08/21/2003US20030157160 Vaccine for modulating between T1 and T2 immune responses
08/21/2003US20030157140 Parenteral preparation having structure of basement polymer layer, carrying layer containing objective substances selected from drugs, aroma chemicals, antigens; carrying layer sandwiched between basement and surface layers
08/21/2003US20030157135 Enhancement and/or extension of antigen-specific Th1-type responses, in particular, CD8+ T cell responses; for treatment of various infectious and neoplastic diseases
08/21/2003US20030157134 Method for treating a non-rhinorrhea cholinergic influenced secretion
08/21/2003US20030157133 For treating, preventing, or inhibiting an infection or disease caused by a gram-positive organism including Streptococcus, Micrococcus, Lactobacillus, Staphylococcus, Bacillus, or Listeria
08/21/2003US20030157131 Interferon inducing genetically engineered attenuated viruses
08/21/2003US20030157129 Wherein carrier protein is also present as free antigen characterised in that the ratio of polysaccharide to carrier protein is from 1:0.3 to 1:2; combined vaccine
08/21/2003US20030157128 Comprises exogenous nucleotide sequences which encode exogenous amino acid sequences; infection of host cell with recombinant Yellow Fever Virus provides for expression of exogenous nucleic acid and production of antigen
08/21/2003US20030157125 Composition containing leishmania lip2a
08/21/2003US20030157124 Chlamydia membrane ATPase and corresponding DNA molecules, which can be used to prevent and treat Chlamydia infection in mammals such as humans
08/21/2003US20030157123 Chlamydia membrane ATPase and corresponding DNA molecules, which can be used to prevent and treat Chlamydia infection in mammals such as humans
08/21/2003US20030157121 Virulence genes, proteins, and their use
08/21/2003US20030157120 Therapeutic compositions for treatment and/or prophylaxis of intestinal disease conditions in animals and birds caused or exacerbated by Lawsonia intracellularis or similar or otherwise related microorganism
08/21/2003US20030157119 Methods for diagnosis and therapy of hematological and virus-associated malignancies
08/21/2003US20030157118 Tumour-specific animal proteins
08/21/2003US20030157117 Immunization against amyloid precursor protien or beta amyloid; treating alzheimer's disease
08/21/2003US20030157116 Tlp peptides and dna sequences coding the same
08/21/2003US20030157115 Carrier with a dendrimeric poly-Lysine enabling multiple epitopes to be covalently attached thereto, a peptide with t epitope(s) and a carbohydrate with a b epitope that is not a sialoside; immunotherapy
08/21/2003US20030157113 Compositions and methods for treatment of neoplastic disease
08/21/2003US20030157110 Methods for the treatment of metabolic disorders, including obesity and diabetes
08/21/2003US20030157108 80-100% of the glycoprotein has a mature core carbohydrate structure which lacks fucose, attached to a Fc region
08/21/2003US20030157105 Amino acid sequences
08/21/2003US20030157104 Treatment of refractory human tumors with epidermal growth factor receptor antagonists
08/21/2003US20030157103 Human amine transporter antibodies
08/21/2003US20030157102 Administering a ligand having a population of activated t cells and binding specificity for the extracellular domain of CD28 to enhance t cell proliferation and increase overall lymphokine levels
08/21/2003US20030157101 Cytotoxic t-lymphocyte-epitopes from anaplastic lymphoma kinase (alk) protein; immunotherapy
08/21/2003US20030157100 Monoclonal antibody inducing apoptosis
08/21/2003US20030157099 Human trk receptors and neurotrophic factor inhibitors
08/21/2003US20030157098 Methods for inhibiting brain tumor growth
08/21/2003US20030157097 Novel remedies for cancer
08/21/2003US20030157095 Invasive and metastic ability of breast cancer cells is proportional to level of peripheral type benzodiazepine receptor expressed, correlates with subcellular localization in that it is found in the nucleus of aggressive tumor cells
08/21/2003US20030157094 Prevention, therapy liver disorders, inflammatory bowel diseases, Crohn's disease; antiulcer agents; rheumatic diseases
08/21/2003US20030157090 Redox systems; accumulation of polypeptide in plant cell; genetic engineering
08/21/2003US20030157089 Polypeptides; inducting immunology response
08/21/2003US20030157077 Induction of chimera mixture; anticancer agents, leukemia
08/21/2003US20030157066 Compositions comprising viruses and methods for concentrating virus preparations
08/21/2003US20030157061 Analgesics, antiinflammatory agents, cardiovascular disorders; anticancer agents
08/21/2003US20030157059 Vaccine; infection therapy
08/21/2003US20030157055 Modified cytokines for use in cancer therapy
08/21/2003US20030157054 Recombinant tumor specific antibody and use thereof
08/21/2003US20030157022 Non-invasive localization of a light-emitting conjugate in a mammal
08/21/2003CA2752553A1 Anti-cd20 antibodies and fusion proteins thereof and methods of use
08/21/2003CA2513198A1 Microorganism for genetic therapeutic treatment of proliferative diseases
08/21/2003CA2492097A1 Signal for packaging of influenza virus vectors
08/21/2003CA2482333A1 Human antibodies for therapy against vaccinia or smallpox
08/21/2003CA2476424A1 Means and methods for altering the motility of the gastrointestinal tract
08/21/2003CA2476366A1 Cancer therapy
08/21/2003CA2476165A1 Mhc class i peptide epitopes from the human 5t4 tumor-associated antigen
08/21/2003CA2475838A1 Cytotoxic t-cell epitopes from chlamydia
08/21/2003CA2475356A1 Human fetal bladder-derived epithelial cells
1 ... 1221 1222 1223 1224 1225 1226 1227 1228 1229 1230 1231 1232 1233 1234 1235 1236 1237 1238 1239 1240 1241 ... 1823